Blog: ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) – marketscreener.com

Item 2.02 Results of Operations and Financial Condition.

On January 10, 2022, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a
press release (the “Press Release”) announcing preliminary unaudited fiscal year
2021 revenue for Crysvita® in the Ultragenyx territories and Dojolvi® global
revenue, cash and investments at 2021 fiscal year end and 2022 revenue guidance
for Crysvita® in the Ultragenyx territories and Dojolvi®. Ultragenyx territories
for Crysvita® include the collaboration revenue from the North American profit
share territory of the United States and Canada and other regions where revenue
from product sales are recognized by the Company, including Latin America and
Turkey, pursuant to the Company’s collaboration and license agreement with Kyowa
Kirin Co., Ltd. The Company expects to report its full year results for the 2021
fiscal year in February 2022. A copy of the Press Release is furnished herewith
as Exhibit 99.1.

The information set forth under Item 2.02 and in Exhibit 99.1 shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, except as shall be expressly set forth by specific
reference in such filing.

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, the Company posted a presentation (the “Presentation”) to
its website at http://www.ultragenyx.com in the “Events and Presentations” subsection
of the “Investors & Media” tab. The Company is scheduled to present the
Presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 10,
2022.

The information set forth under Item 7.01 and in the Presentation shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, except as shall be expressly set forth by specific
reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No. Description
99.1          Press Release, dated January 10, 2022.
104         The cover page from the Company's Current Report on Form 8-K dated
            January 10, 2022 formatted in Inline XBRL.





——————————————————————————–

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s